Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18–64 years) and older adults (≥65 years): two multicentre, randomised phase 3 trials

Brian J. Ward; А. И. Макарков; Annie Séguin; Stéphane Pillet; Sonia Trépanier; Jiwanjeet K. Dhaliwall; Michael Libman; Timo Vesikari; Nathalie Landry

doi:10.1016/s0140-6736(20)32014-6

Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18–64 years) and older adults (≥65 years): two multicentre, randomised phase 3 trials

Authors: Brian J. Ward, А. И. Макарков, Annie Séguin, Stéphane Pillet, Sonia Trépanier, Jiwanjeet K. Dhaliwall, Michael Libman, Timo Vesikari, Nathalie Landry - The Lancet 2020 cited by 192

Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18–64 years) and older adults (≥65 years): two multicentre, randomised phase 3 trials | Litlas